GlassScriptPhysician profile
Patrick J Blomberg
NPI 1497746010
$5,892.84
in general payments reported to CMS, 2019-2025
28 companies · $630 in 2025
The $630 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,630 · 2020: $93.06 · 2021: $505 · 2022: $870 · 2023: $1,343 · 2024: $822 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,783 · Travel and Lodging: $12.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,782.78 |
| Travel and Lodging | $12.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,476.49 | 2019-2025 | Ensite Precision, Aveir, Jot Dx |
| Medtronic, INC. | $565.97 | 2021-2024 | Arctic Front Advance, Linq II, Attain Command + Surevalve |
| Janssen Pharmaceuticals, INC | $544.64 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $428.85 | 2019-2025 | |
| Amgen INC. | $403.66 | 2019-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $323.79 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $296.22 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $273.06 | 2019-2025 | Farxiga |
| Boston Scientific Corporation | $265.00 | 2024-2025 | Acuity Steerable, Farapulse |
| Merck Sharp & Dohme LLC | $188.98 | 2021-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $153.26 | 2021-2023 | Onpattro |
| Esperion Therapeutics, INC. | $137.46 | 2022-2025 | Nexletol |
| Kiniksa Pharmaceuticals, LTD. | $105.90 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $100.65 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $95.75 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $92.02 | 2022-2024 | Ozempic, Wegovy |
| Medtronic Vascular, INC. | $91.89 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.23 | 2022-2023 | |
| Amarin Pharma, INC. | $54.97 | 2019 | |
| Scpharmaceuticals INC. | $36.66 | 2024 | |
| Abiomed | $33.33 | 2024 | Impella |
| Janssen Scientific Affairs, LLC | $30.93 | 2023 | Xarelto |
| Ethicon US, LLC | $30.38 | 2023 | Dermabond |
| Terumo Medical Corporation | $27.53 | 2025 | Glidesheath Slender |
| Chiesi USA, INC. | $25.42 | 2025 | Kengreal, Cleviprex |
| Actelion Pharmaceuticals US, INC. | $21.41 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.03 | 2021 | |
| Biosense Webster, INC. | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Blomberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.